From Nasdaq: 2025-06-07 15:05:00

Validea’s guru fundamental report for Blueprint Medicines Corp (BPMC) shows that the stock rates highest using the P/B Growth Investor model by Partha Mohanram. BPMC is a mid-cap growth stock in the Biotechnology & Drugs industry, with a rating of 55% based on underlying fundamentals and valuation. The analysis highlights the stock’s strong points like book-to-market ratio, return on assets, and cash flow from operations to assets. However, it falls short in areas like return on assets variance and sales variance. Partha Mohanram, a renowned academic, developed a growth model that has shown significant market outperformance.



Read more at Nasdaq: BPMC Quantitative Stock Analysis | Nasdaq